Researchers Are Studying Whether Paxlovid Can Treat Long COVID
Months after catching COVID-19 in December 2021, Lavanya Visvabharathy was still testing positive on antigen tests and suffering from symptoms including headaches and intense fatigue. So Visvabharathy, a research assistant professor of neurology at the Northwestern University Feinberg School of Medicine who has studied Long COVID since 2020, decided to conduct an experiment on herself. She asked her doctor to prescribe her Paxlovid, an antiviral therapy that can treat COVID-19 by inhibiting replication of the virus that causes it. Paxlovid is meant to keep high-risk patients with acute COVID-19 from developing severe disea...
Source: TIME: Health - November 29, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

The N Protein, A New Target For Anti-Covid Drugs
FDA-approved drug inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 29, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news

Director ’s Innovation Speaker Series: HIV-1 and SARS-CoV-2 Effects on Brain and Mind Health: A Tale of Two Viruses
Serena Spudich, M.D., M.A. discussed similarities and differences between the HIV-1 and SARS-CoV-2 viruses and how that knowledge could inform research on SARS-CoV-2. (Source: National Institute of Mental Health)
Source: National Institute of Mental Health - November 28, 2022 Category: Psychiatry Authors: National Institute of Mental Health Source Type: news

WHO Renames Monkeypox as mpox, Citing Racism Concerns
LONDON — The World Health Organization has renamed monkeypox as mpox, citing concerns the original name of the decades-old animal disease could be construed as discriminatory and racist. The U.N. health agency said in a statement Monday that mpox was its new preferred name for monkeypox, saying that both monkeypox and mpox would be used for the next year while the old name is phased out. WHO said it was concerned by the “racist and stigmatizing language” that arose after monkeypox spread to more than 100 countries. It said numerous individuals and countries asked the organization “to propose a way f...
Source: TIME: Health - November 28, 2022 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized healthscienceclimate monkeypox wire Source Type: news

SARS-CoV-2 variants of public health interest, UKHSA (updated 25th November 2022)
Details of the variants of public health interest. 25 November 2022Added latest update. 1 November 2022Updated XQW (BA.2xDelta recombinant) to XAW (BA.2xDelta recombinant) in 9 September and 7 October publications, and Omicron and Delta recombinant XQW to Omicron and Delta recombinant XAW in 28 October report. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 28, 2022 Category: Consumer Health News Source Type: news

Effect of Frequent SARS-CoV-2 Testing in LTC Facilities Effect of Frequent SARS-CoV-2 Testing in LTC Facilities
Does more frequent testing result in a reduction of SARS-CoV-2 cases among long-term care residents and staff?Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 28, 2022 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Africa: Covid Nasal Sprays May One Day Prevent and Treat Infection. Here's Where the Science Is Up to
[The Conversation Africa] We have vaccines to boost our immune response to SARS-CoV-2, the virus that causes COVID. We have medicines you can take at home (and in hospital) to treat COVID. Now researchers are trialling something new. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 28, 2022 Category: African Health Source Type: news

Links 11/26/2022
Over 1 billion people believe in witchcraft — especially in places with weak institutions ZME Science Climate/Environment Biden administration quietly approves huge Texas oil export project The Texas Tribune Water #COVID-19 Molecular and cellular similarities in the brain of SARS-CoV-2 and…#zmescience #institutionszme #weakinstitutions #science #zme #witchcraft #weak #institutions #environment #hellenicshipping (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2022 Category: Consumer Health News Source Type: news

Headache as a COVID-19 Onset Symptom and Post-COVID-19 Symptom Headache as a COVID-19 Onset Symptom and Post-COVID-19 Symptom
This study investigated differences in headache as a COVID-19 onset symptom and as a post-COVID-19 symptom in previously hospitalized patients infected by different SARS-CoV-2 variants.Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 25, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Successful Liver Transplantation in Patients With SARS-CoV-2 Successful Liver Transplantation in Patients With SARS-CoV-2
Successful liver transplantation was performed in two patients with asymptomatic, active SARS-CoV-2 infection.American Journal of Transplantation (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 25, 2022 Category: Transplant Surgery Tags: Transplantation Journal Article Source Type: news

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment
Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now. Researchers of the University of Bristol-led study, published in Science Advances today [23 November], say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses — from the 2002 SARS-CoV outbreak to Omicron, the current variant of SARS-CoV-2, as well as dangerous variants that may emerge in future. (Source: University of Bristol news)
Source: University of Bristol news - November 23, 2022 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty of Life Sciences, School of Cellular and Molecular Medicine, Institutes, Institutes, Bristol BioDesign Institute, Institutes, Elizabeth Bl Source Type: news

First Real-World Data Show That the Bivalent Booster Is Effective
In a report published in the Morbidity and Mortality Weekly Report, scientists at the U.S. Centers for Disease Control and Prevention (CDC) provided the first real-world evidence on the effectiveness of the bivalent booster shot that the CDC and the U.S. Food and Drug Administration (FDA) authorized in September. The researchers conclude that the bivalent booster, which contains genetic material from both the original SARS-CoV-2 virus and the Omicron BA.4/5 variants, is effective in protecting people from severe COVID-19. The relative effectiveness among people ages 18 to 49 who received the bivalent booster—compared...
Source: TIME: Health - November 23, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study
Study of 660 children in Switzerland found 4.4% of adolescents with Covid experienced symptoms lasting over 4 weeks; most frequently fatigue, headache and loss of smell. The authors say this represents a large absolute number, and should raise awareness and concern. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 23, 2022 Category: Consumer Health News Source Type: news

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment
Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now. Researchers of the University of Bristol-led study, published in Science Advances today, say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses - from the 2002 SARS-CoV outbreak to Omicron, the current variant of SARS-CoV-2, as well as dangerous variants that may emerge in future. (Source: World Pharma News)
Source: World Pharma News - November 23, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Early SARS-CoV-2 Reinfections and Retesting Policies Early SARS-CoV-2 Reinfections and Retesting Policies
Early reinfections with SARS-CoV-2 can occur within 60 days, as highlighted by this case report. Is it time to revise retesting policies?Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 23, 2022 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news